

Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

M. Vogelhuber · S. Feyerabend · A. Stenzl · T. Suedhoff · M. Schulze · J. Huebner · R. Oberneder · W. Wieland · S. Mueller · F. Eichhorn · H. Heinzer · K. Schmidt · M. Baier · A. Ruebel · K. Birkholz · A. Bakhshandeh-Bath · R. Andreesen · W. Herr · A. Reichle

Published online: 5 February 2015
© Springer Science+Business Media Dordrecht 2015

Erratum to: Cancer Microenvironment
DOI 10.1007/s12307-014-0161-7

The original publication of this article ([10.1007/s12307-014-0161-7](https://doi.org/10.1007/s12307-014-0161-7)) unfortunately contained an error. Figures 1 and 2 are the same, the correct figures are presented here.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s12307-014-0161-7>.

M. Vogelhuber · R. Andreesen · W. Herr · A. Reichle (✉)
Department of Hematology and Oncology, University Hospital
Regensburg, Franz-Josef-Strauß-Allee 11,
93053 Regensburg, Germany
e-mail: albrecht.reichle@ukr.de

S. Feyerabend · A. Stenzl
Department of Urology, University Hospital Tuebingen,
Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany

T. Suedhoff
Department of Hematology and Oncology, Hospital Passau,
Innstrasse 76, 94032 Passau, Germany

M. Schulze
Outpatient Center for Urology and Oncology, Hauptstrasse 10,
04416 Markkleeberg, Germany

J. Huebner
Department of Oncology, J. W. Goethe University,
Theodor-Stern-Kai 7, 60323 Frankfurt, Germany

R. Oberneder
Urologic Hospital München-Planegg, Germeringer Str. 32,
82152 Planegg, Germany

W. Wieland
Department of Urology, Hospital St. Josef,
University Regensburg, Landshuter Strasse 65,
93053 Regensburg, Germany

S. Mueller
Department of Urology, University Hospital Bonn,
Sigmund-Freud-Strasse 25, 53105 Bonn, Germany

F. Eichhorn
Outpatient Center, Rinckstrasse 7-9, 83435 Bad
Reichenhall, Germany

H. Heinzer
Martini-Clinic at University Hospital Hamburg-Eppendorf,
Martinistrasse 52, 20246 Hamburg, Germany

K. Schmidt · M. Baier · A. Ruebel · K. Birkholz
Novartis Pharma GmbH, Roonstrasse 25,
90429 Nuernberg, Germany

A. Bakhshandeh-Bath
Outpatient Center for Medical Oncology, Waitzstrasse 22,
22607 Hamburg, Germany

Fig. 1 Study design including the main inclusion and exclusion criteria. ECOG Eastern cooperative oncology group performance status, CRPC Castration-resistant prostate cancer, PSA Prostate-specific antigen, AE Adverse event, SAE Serious adverse event





Fig. 2 Proportion of patients discontinuing study drug. One patient is still ongoing (at the time of manuscript submission Oct 2014). Pts Patients, PSA Prostate-specific antigen